BridgeBio secondary offering by KKR Genetic Disorder L.P. priced at $78.00 per share

BridgeBio Pharma, Inc. disclosed in an 8-K filed August 17, 2026 that on August 13, 2026 it and selling stockholder KKR Genetic Disorder L.P. entered into an underwriting agreement with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC, acting as representatives of the underwriters, for an offering of 5,000,000 shares of BridgeBio common stock, par value $0.001 per share, sold by the selling stockholder at a price to the public of $78.00 per share.¹

BridgeBio said it will not receive any of the proceeds from the sale of the shares being offered by the selling stockholder.¹ The sale of the shares is expected to be completed on August 17, 2026.¹

The offering draws on BridgeBio's shelf registration. The offering was made under the company's effective shelf registration statement on Form S-3ASR, File No. 333-297701, using a prospectus dated July 24, 2026 and a prospectus supplement dated August 13, 2026 that was filed on August 14, 2026.¹

As part of the deal, BridgeBio made customary representations, warranties and covenants concerning the company and the registration statement, and agreed to indemnify the underwriters against certain liabilities, including under the Securities Act of 1933.¹ Goodwin Procter LLP provided a legal opinion on the legality of the shares being sold by the selling stockholder.¹

BridgeBio issued a press release on August 13, 2026 announcing the launch of the offering, and a second press release on August 14, 2026 announcing the pricing of the offering.¹ The filing does not describe any corporate relationship between BridgeBio and KKR Genetic Disorder L.P. beyond its role as selling stockholder.